Renal complications of Castleman’s disease (angiofollicular lymph node hyperplasia) are uncommon. The reported cases are very heterogeneous and their renal pathology ranged from minimal change disease, mesangial proliferative glomerulonephritis, to amyloidosis. We have previously reported two cases of Castleman’s disease with renal complications. We now present two more such cases. In contrast to other reports, all our cases are of the plasma cell type and their renal pathology showed remarkable similarities, namely mesangial proliferation, interstitial plasma cell infiltration and negative immunofluorescence. The level of serum interleukin-6 (IL-6) in both patients was elevated at presentation and came down with immunosuppressive therapy.

Castleman B, Iverson K, Menendez VP: Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer 1956;9:822–830.
Keller AR, Hochholzer L, Castleman B: Hyaline-vascular and plasma cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972;29:670–683.
Frizzera G, Peterson BA, Bayrd ED, Goldman A: A systemic lymphoproliferative disorder with morphological features of Castleman’s disease: Clinical findings and clinicopathological correlation in 15 patients. J Clin Oncol 1985;3:1202–1216.
Humpherys SR, Holley KE, Smith LH, Mcilrath DC: Mesenteric angiofollicular lymph node hyperplasia (lymphoid hamartoma) with nephrotic syndrome. Mayo Clin Proc 1975;50:317–321.
Weisenberger DD: Membranous nephropathy: Its association with multicentric angiofollicular lymph node hyperplasia. Arch Pathol Lab Med 1979;103:591–594.
Diebold J, Tulliez M, Bernadou A, Audouin J, Tricot G, Reynes M, Bilski-Pasquier G: Angiofollicular and plasmacytic polyadenopathy: A pseudotumourous syndrome with dysimmunity. J Clin Pathol 1980;33:1068–1076.
Pilon VA, Gomez LG, Butler JJ: Systemic amyloidosis associated with a benign mesenteric lymphoid mass. Am J Clin Pathol 1982;78:112–116.
Summerfield GP, Taylor W, Bellingham AJ, Goldsmith HJ: Hyaline-vascular variant of angiofollicular lymph node hyperplasia with systemic manifestations and response to corticosteroids. J Clin Pathol 1983;36:1005–1011.
Chan WC, Hargreaves H, Keller J: Giant lymph node hyperplasia with unusual clinicopathologic features. Cancer 1984;53:2135–2139.
Chan KW, Chan MK, Choy DT: Nephrotic syndrome associated with angiofollicular lymph node hyperplasia. Pathology 1987;19:429–432.
Ruggieri G, Barsotti P, Coppola G, Spinelli C, Balducci A, Ventola FR, d’Adama G, Tata MV, Marinozzi V: Membranous nephropathy associated with giant lymph node hyperplasia: A case report with histological and ultrastructural studies. Am J Nephrol 1990;10:323–328.
Tsukamoto Y, Hanada N, Nomura Y, Hiki Y, Kasai K, Shigematsu H, Kobayashi Y: Rapidly progressive renal failure associated with angiofollicular lymph node hyperplasia. Am J Nephrol 1991;11:430–436.
Said R, Tarawneh M: Membranoproliferative glomerulonephritis associated with multicentric angiofollicular lymph node hyperplasia: Case report and review of the literature. Am J Nephrol 1992;12:466–470.
Chan TM, Cheng IK, Wong KL, Chan KW: Resolution of membranoproliferative glomerulonephritis complicating angiofollicular lymph node hyperplasia (Castleman’s disease). Nephron 1993;65:628–632.
Kinney MC, Hummell DS, Villiger PM, Hourigan A, Rollins-Smith L, Glick AD, Lawton AR: Increased interleukin-6 (IL-6) production in a young child with clinical and pathologic features of multicentric Castleman’s disease. J Clin Immunol 1994;14:382–390.
West KP, Morgan DR, Launder I: Angiofollicular lymph node hyperplasia with amyloidosis. Postgrad Med J 1989;65:108–111.
Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Tacho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T, Kishimoto S, Hirano T, Kishimoto T: Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood 1989;74:1360–1367.
Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW: Dysregulated interleukin 6 expression produces a syndrome resembling Castleman’s disease in mice. J Clin Invest 1990;86:592–599.
Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, Hayden K, Jayannath S, Barlogie B: Brief Report: alleviation of systemic manifestations of Castleman’s disease by monoclonal anti-interleukin 6 antibody. N Engl J Med 1994;330:602–605.
Screpanti I, Musiani P, Bellavia D, Cappelletti M, Aiello FB, Maroder M, Frati L, Modesti A, Gulino A, Poli V: Inactivation of the IL-6 gene prevents development of multicentric Castleman’s disease in C/EBPβ-deficient mice. J Exp Med 1996;184:1561–1566.
Hirano T, Akira S, Taga T, Kishimoto T: Biological and clinical aspects of interleukin 6. Immunol Today 1990;11:443–449.
Horri Y, Muraguchi A, Iwano M, Matsuda T, Hirayama T, Yamada H, Fujii Y, Dohi K, Ishikawa H, Ohmoto Y, Yoshizaki K, Hirano T, Kishimoto T: Involvement of interleukin-6 in mesangial proliferative glomerulonephritis. J Immunol 1989;143:3949–3955.
Chen WP, Chen A, Lin CY: In vitro effects of interleukins on human mesangial cells: implications for glomerulonephritis. J Pathol 1995;175:327–337.
Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994;266:1865–1869.
Chen KT: Multicentric Castleman’s disease and Kaposi’s sarcoma. Am J Surg Pathol 1984;8:287–293.
Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, d’Agay MF, Clauvel JP, Raphael M, Degos L, Sigaux F: Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood 1995;86:1276–1280.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.